A direct mechanistic link between growth control and a tumor cell immune function: Increased interleukin-8 secretion accounts for elimination of Oct-1 antisense transformants from Scid mice

Anticancer Research

Volumn 26, Issue 3 A, 2006, Pages 1733-1738

  Palubin, Kimberly M ^a   Goodwin, Bonnie L ^a   Niesen, Melissa I ^a   Le, Elizabeth A ^a   Osborne, Aaron R ^a   Blanck, George ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Interleukin 8; Oct 1; Oct 1 antisense transformants; Retinoblastoma protein; Tumor cell immune functions; Tumor growth

Indexed keywords

CARRIER PROTEIN; HISTONE H2B; HLA DR ANTIGEN; INTERLEUKIN 8; PROTEIN OCT 1; SMALL NUCLEAR RIBONUCLEOPROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CARCINOGENICITY; CELL CYCLE S PHASE; CELL GROWTH; CELLULAR IMMUNITY; COLONY FORMATION; CONTROLLED STUDY; DNA BINDING; GROWTH REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT PLASMID; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNOLOGY;

ANIMALS; CELL GROWTH PROCESSES; DNA, ANTISENSE; HUMANS; INTERLEUKIN-8; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; OCTAMER TRANSCRIPTION FACTOR-1; TRANSFORMATION, GENETIC; TRANSPLANTATION, HETEROLOGOUS; URINARY BLADDER NEOPLASMS;

EID: 33745608463     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Blanck G: Mutations and regulatory anomalies effecting tumor cell immune functions. Cancer Immunol Immunother 53: 1-16, 2004.
2. Coenjaerts FE, van Oosterhout JA and Van der Vliet PC: The Oct-1 POU domain stimulates adenovirus DNA replication by a direct interaction between the viral precursor terminal protein-DNA polymerase complex and the POU homeodomain. EMBO J 13: 5401-5409, 1994.
3. Das G and Herr W: Enhanced activation of the human histone H2B promoter by an Oct-1 variant generated by alternative splicing. J Biol Chem 268: 25026-25032, 1993.
4. Herr W and Cleary MA: The POU domain: versatility in transcriptional regulation by a flexible two-in-one DNA-binding domain. Genes Dev 9: 1679-1693, 1995.
5. Lee L-F, Hellendall RP, Wang Y, Haskill JS, Mukaida N, Matsushima K and Ting J-P: IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J Immunol 164: 2769-2775, 2000.
6. Murphy S: Differential in vivo activation of the class II and class III snRNA genes by the POU-specific domain of Oct-1. Nucleic Acids Res 25: 2068-2076, 1997.
7. Niesen MI, Osborne AR, Yang H, Rastogi S, Chellappan S, Cheng JQ, Boss JM and Blanck G: Activation of a methylated promoter mediated by a sequence specific DNA binding protein: RFX. J Biol Chem 280 (47): 38914-38922, 2005.
8. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R and Yu H: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008, 2002.
9. Osborne A, Zhang H, Yang WM, Seto E and Blanck G: Histone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase I-hypersensitive chromatin conformation. Mol Cell Biol 21: 6495-6506, 2001.
10. Osborne AR, Zhang H, Fejer G, Palubin KM, Niesen MI and Blanck G: Oct-1 maintains an intermediate, stable state of HLA-DRA promoter repression in Rb-defective cells: an Oct-1-containing repressosome that prevents NF-Y binding to the HLA-DRA promoter. J Biol Chem 279: 28911-28919, 2004.
11. Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP and Gabrilovich DI: Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 760: 1224-1232, 1998.
12. Qin XF, Luo Y, Suh H, Wayne J, Misulovin Z, Roeder RG and Nussenzweig MC: Transformation by homeobox genes can be mediated by selective transcriptional repression. EMBO J 13: 5967-5976, 1994.
13. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T and Kerbel RS: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55: 4575-4580, 1995.
14. Segil N, Roberts SB and Heintz N: Cell-cycle-regulated phosphorylation of the transcription factor Oct-1. Cold Spring Harb Symp Quant Biol 56: 285-292, 1991.
15. Sturm RA, Das G and Herr W: The ubiquitous octamer-binding protein Oct-1 contains a POU domain with a homeo box subdomain. Genes Dev 2: 1582-1599, 1988.
16. Wu GD, Lai EJ, Huang N and Wen X: Oct-1 and CCAAT/enhancer-binding protein (C/EBP) bind to overlapping elements within the interleukin-8 promoter. The role of Oct-1 as a transcriptional repressor. J Biol Chem 272: 2396-2403, 1997.
17. Zhang H, Shepherd AT, Eason DD, Wei S, Diaz JI, Djeu JY, Wu GD and Blanck G: Retinoblastoma protein expression leads to reduced Oct-1 DNA-binding activity and enhances interleukin-8 expression. Cell Growth Differ 10: 457-465, 1999.
18. Zhang H, Wei S, Sun J, Coppola D, Zhong B, Wu GD, Goodwin B, Sebti S, Djeu JY and Blanck G: Retinoblastoma protein activation of interleukin 8 expression inhibits tumor cell survival in nude mice. [In Process Citation]. Cell Growth Differ 11: 635-699, 2000.